BenevolentAI société anonyme (id:90 BAI)
0.732 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/22/2024 1:46:18 AM)
Exchange closed, opens in 7 hours 13 minutes
About BenevolentAI société anonyme
Market Capitalization 94.87M
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
| Headquarters (address) |
4-8 Maple Street London W1T 5HD United Kingdom |
| Phone | 44 20 3781 9360 |
| Website | https://www.benevolent.com |
| Employees | 180 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | BAI |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 0.460 - 2.66 |
| Market Capitalization | 94.87M |
| P/E trailing | -1.41 |
| P/E forward | -2.48 |
| Price/Sale | 19.49 |
| Price/Book | 1.35 |
| Beta | 0.888 |
| EPS | -0.640 |
| EPS United Kingdom (ID:3, base:637) | 0.428 |